We claim:

1. ~~A method of treating a subject suffering from an autoimmune disorder comprising administering to said subject in need of a therapeutically effective amount of~~ Use of a PRMT5 inhibitor in the manufacture of a medicament for the treatment of an autoimmune disorder, wherein a therapeutically effective amount of the medicament is to be administered to a subject in need thereof.

2. The ~~method~~ use of claim 1, wherein the PRMT5 inhibitor is (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof.

3. The ~~method~~ use of claim 1 or 2, wherein the autoimmune disorder is selected from the group consisting of psoriasis, atopic dermatitis, alopecia areata, ankylosing spondylitis, asthma, type 1 diabetes, multiple sclerosis, celiac disease, scleroderma, hidradenitis suppurativa, vitiligo, dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, and inflammatory bowels disease.

4. The ~~method~~ use of claim 3, wherein the autoimmune disorder is psoriasis.

5. The ~~method~~ use according to any of the preceding claims, wherein said therapeutically effective amount is to be administered enterally, parenterally, or topically.

6. The ~~method~~ use according to claim 5, wherein said enteral administration is to be administered orally or rectally.

7. The ~~method~~ use according to claim 6, wherein said oral administration is to be administered as a tablet, a capsule, or a liquid dosage form.

8. The ~~method~~ use according to claim 5, wherein said parenteral administration is to be administered intravenously or intraarticularly.

9. The ~~method~~ use according to claim 5, wherein said topical administration is to be administered as a solution, a cream, an ointment, a gel, a lotion, a suspension, or an emulsion.

10. The ~~method~~ use according to any of the preceding claims, wherein said subject is to be administered a therapeutically effective amount from about 0.5 mg to about 120 mg.

11. The ~~method~~ use according to claim 10, wherein said therapeutically effective amount is selected from the group consisting of about 0.5 mg, 1 mg, 2 mg, 4 mg, 6 mg, 8mg, 10 mg, 16 mg, 32 mg, 60 mg, 80 mg, and 120 mg.

12. The ~~method~~ use according to claim 11, wherein said therapeutically effective amount is about 12 mg.

13. The ~~method~~ use according to claim 11, wherein said therapeutically effective amount is about 10 mg.

14. The ~~method~~ use according to claim 11, wherein said therapeutically effective amount is about 8 mg.

15. The ~~method~~ use according to claim 11, wherein said therapeutically effective amount is about 6 mg.

16. The ~~method~~ use according to claim 11, wherein said therapeutically effective amount is about 4 mg.

17. The ~~method~~ use according to claim 11, wherein said therapeutically effective amount is about 1 mg.

18. The ~~method~~ use according to any one of claims 10-17, wherein said therapeutically effective amount is to be administered once daily (QD).

19. The ~~method~~ use according to any one of claims 10-17, wherein said therapeutically effective amount is to be administered twice daily (BID).

20. The ~~method~~ use according to any one of claims 2-19, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is to be administered for 1 to 28 days.

21. The ~~method~~ use according to any one of claims 2-19, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is to be administered for 1-6 weeks.

22. The ~~method~~ use according to any one of claims 2-19, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is to be administered for 1-6 months.

23. The ~~method~~ use according to claim 22, wherein said (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable salt thereof is to be administered for 1-4 months.